MaaT Pharma, a French biotechnology company in advanced clinical stage (Phase 3), a pioneer in the development of drugs in the restoration of the intestinal microbiota to improve the survival of cancer patients, and Skyepharma, a CDMO company specializing in the formulation and manufacturing of complex and controlled-release drugs, announce today the signing of a partnership to build the plant, to date, the largest in France entirely dedicated to the production of full-ecosystem therapies derived from the microbiota, in the compliance with pharmaceutical standards (cGMP).
For more information on MaaT Pharma, contact [email protected]